Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT02049489 | A Study of ICT-121 Dendritic Cell Vaccine in Recurrent Glioblastoma | PHASE1 | COMPLETED | 20 | — | — | Dec 1, 2013 | Mar 1, 2017 | Aug 13, 2018 | 6 | United States |
To assess safety of the autologous ICT-121 DC vaccine the following will be monitored: Serious Adverse events, treatment emergent adverse events, treatment related toxicities
| Arm | Type | Description |
|---|---|---|
| ICT-121 DC vaccine | EXPERIMENTAL | Autologous dendritic cells pulsed with peptide antigens |
| Name | Type | Description |
|---|---|---|
| ICT-121 DC vaccine | BIOLOGICAL | autologous dendritic cells pulsed with peptide antigens |
Inclusion Criteria: 1. Any recurrence of a glioblastoma multiforme 2. ≥ 18 years of age 3. Human leukocyte antigen HLA A2 positive 4. Karnofsky Performance Score (KPS) of ≥ 70% 5. Baseline hematologic studies and chemistry profiles must meet the following criteria: * hemoglobin (Hgb) \> 9.9 g/d...